[Comment] ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?

Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) –programmed cell death ligand-1 (PD-L1) axis have dramatically expanded the therapeutic armamentarium for non-small-cell lung cancer (NSCLC), and are now standard treatments for patients with advanced disease.1 However, most patients with NSCLC do not respond to PD-1 or PD-L1 inhibitors—an obser vation motivating ongoing research efforts to identify biomarkers of response. Until now, such efforts have largely centred on assessments of PD-L1 expression, although several other biomarkers are under investigation.

Source: The Lancet Oncology - March 12, 2018 Category: Cancer & Oncology Authors: Jessica J Lin, Justin F Gainor Tags: Comment Source Type: research